| 1.81 0.01 (0.56%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.63 | 1-year : | 3.07 |
| Resists | First : | 2.25 | Second : | 2.63 |
| Pivot price | 1.96 |
|||
| Supports | First : | 1.64 | Second : | 1.37 |
| MAs | MA(5) : | 1.9 |
MA(20) : | 1.92  |
| MA(100) : | 2.03 |
MA(250) : | 1.9 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 13.5 |
D(3) : | 20.5 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 2.91 | Low : | 0.83 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ERNA ] has closed above bottom band by 18.0%. Bollinger Bands are 6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.85 - 1.86 | 1.86 - 1.87 |
| Low: | 1.73 - 1.75 | 1.75 - 1.76 |
| Close: | 1.79 - 1.81 | 1.81 - 1.83 |
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Wed, 08 May 2024
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board - Yahoo Finance
Sun, 03 Mar 2024
symbol__ Stock Quote Price and Forecast - CNN
Tue, 20 Feb 2024
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors - Yahoo Finance
Wed, 20 Dec 2023
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer - Yahoo Finance
Thu, 14 Dec 2023
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing - GlobeNewswire
Tue, 11 Jul 2023
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -11 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.41e+006 (%) |
| Held by Institutions | 2.96e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -4.25 |
| Profit Margin | 0 % |
| Operating Margin | -12 % |
| Return on Assets (ttm) | 312.7 % |
| Return on Equity (ttm) | -40.9 % |
| Qtrly Rev. Growth | 154.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -36.81 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.104e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -0.43 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 0 |
| Dividend | 54500 |
| Forward Dividend | 47720 |
| Dividend Yield | 3011050% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|